Trinity biotech welcomes avinash kale as continuous glucose monitor programme director to advance innovation and development

Dublin, ireland, may 08, 2024 (globe newswire) -- trinity biotech plc (nasdaq: trib) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of avinash kale as continuous glucose monitor (cgm) programme director. his appointment is a critical step forward in advancing the company's recently acquired cgm technology and in driving its innovation and development to bring an advanced cgm solution to the global market.
TRIB Ratings Summary
TRIB Quant Ranking